HUP0200517A3 - Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 - Google Patents
Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907Info
- Publication number
- HUP0200517A3 HUP0200517A3 HU0200517A HUP0200517A HUP0200517A3 HU P0200517 A3 HUP0200517 A3 HU P0200517A3 HU 0200517 A HU0200517 A HU 0200517A HU P0200517 A HUP0200517 A HU P0200517A HU P0200517 A3 HUP0200517 A3 HU P0200517A3
- Authority
- HU
- Hungary
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- prodrugs
- fluorophenyl
- alpha
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000002400 serotonin 2A antagonist Substances 0.000 title 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/021608 WO2000021930A1 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200517A2 HUP0200517A2 (en) | 2002-06-29 |
| HUP0200517A3 true HUP0200517A3 (en) | 2002-12-28 |
Family
ID=22268079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200517A HUP0200517A3 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121345A1 (cs) |
| JP (1) | JP2002527422A (cs) |
| KR (1) | KR100515429B1 (cs) |
| CN (1) | CN1160333C (cs) |
| AU (1) | AU1083099A (cs) |
| BR (1) | BR9816049A (cs) |
| CA (1) | CA2347469C (cs) |
| CZ (1) | CZ20011331A3 (cs) |
| EA (1) | EA003667B1 (cs) |
| EE (1) | EE200100219A (cs) |
| HR (1) | HRP20010278A2 (cs) |
| HU (1) | HUP0200517A3 (cs) |
| IL (2) | IL142479A0 (cs) |
| NO (1) | NO320417B1 (cs) |
| NZ (1) | NZ510631A (cs) |
| PL (1) | PL193306B1 (cs) |
| SK (1) | SK5082001A3 (cs) |
| TR (1) | TR200101047T2 (cs) |
| UA (1) | UA57859C2 (cs) |
| WO (1) | WO2000021930A1 (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| CN102241667B (zh) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
| CN106892897A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种羟哌吡酮游离碱新晶型及其制备方法 |
| CN106928187A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种盐酸羟哌吡酮新晶型及其制备方法 |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| JP7846211B2 (ja) | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2083698C (en) * | 1990-06-01 | 1997-11-04 | Albert A. Carr | (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
-
1998
- 1998-10-14 CA CA002347469A patent/CA2347469C/en not_active Expired - Fee Related
- 1998-10-14 IL IL14247998A patent/IL142479A0/xx active IP Right Grant
- 1998-10-14 EA EA200100361A patent/EA003667B1/ru not_active IP Right Cessation
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/pt not_active Application Discontinuation
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/cs unknown
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/ja active Pending
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 CN CNB988142740A patent/CN1160333C/zh not_active Expired - Fee Related
- 1998-10-14 HR HR20010278A patent/HRP20010278A2/hr not_active Application Discontinuation
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/hu unknown
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/xx unknown
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/en not_active Ceased
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/ko not_active Expired - Fee Related
- 1998-10-14 EE EEP200100219A patent/EE200100219A/xx unknown
- 1998-10-14 PL PL347318A patent/PL193306B1/pl not_active IP Right Cessation
- 1998-10-14 EP EP98953458A patent/EP1121345A1/en not_active Withdrawn
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/sk not_active Application Discontinuation
- 1998-10-14 UA UA2001042522A patent/UA57859C2/uk unknown
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2347469C (en) | 2006-02-28 |
| KR20010106517A (ko) | 2001-11-29 |
| HK1039332A1 (en) | 2002-04-19 |
| PL193306B1 (pl) | 2007-01-31 |
| CA2347469A1 (en) | 2000-04-20 |
| IL142479A0 (en) | 2002-03-10 |
| CN1160333C (zh) | 2004-08-04 |
| IL142479A (en) | 2006-06-11 |
| NO20011805L (no) | 2001-06-08 |
| NO320417B1 (no) | 2005-12-05 |
| NO20011805D0 (no) | 2001-04-09 |
| CZ20011331A3 (cs) | 2001-08-15 |
| CN1314887A (zh) | 2001-09-26 |
| TR200101047T2 (tr) | 2001-08-21 |
| EA200100361A1 (ru) | 2001-10-22 |
| PL347318A1 (en) | 2002-03-25 |
| AU1083099A (en) | 2000-05-01 |
| UA57859C2 (uk) | 2003-07-15 |
| HRP20010278A2 (en) | 2002-06-30 |
| WO2000021930A1 (en) | 2000-04-20 |
| EP1121345A1 (en) | 2001-08-08 |
| HUP0200517A2 (en) | 2002-06-29 |
| JP2002527422A (ja) | 2002-08-27 |
| EA003667B1 (ru) | 2003-08-28 |
| NZ510631A (en) | 2003-07-25 |
| BR9816049A (pt) | 2001-07-03 |
| KR100515429B1 (ko) | 2005-09-20 |
| SK5082001A3 (en) | 2001-11-06 |
| EE200100219A (et) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG24533A (en) | Piperdine derivatives useful as CCR 5 antagonists | |
| HUP9603298A3 (en) | Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions | |
| EP1093803A3 (fr) | Composition cosmétique contenant un antagoniste des récepteurs du neuropeptide Y | |
| HUP9701281A2 (en) | Piperidine derivatives as neurokinin antagonists and pharmaceutical compositions containing them | |
| AU2143295A (en) | Neurokinin receptor antagonists | |
| IL122940A0 (en) | Paroxetine controlled release compositions | |
| AU5274499A (en) | Therapeutic chemokine receptor antagonists | |
| HUP0101688A3 (en) | Heterocyclically substituted amides and their use for producing pharmaceutical compositions | |
| HUP0400349A3 (en) | Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them | |
| AU5326100A (en) | Pharmaceutical compositions and methods for use | |
| AUPP968699A0 (en) | Therapeutic compositions and method for their preparation | |
| PL352432A1 (en) | Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them | |
| HUP0004648A3 (en) | 3-substituted tetrahydropyridopyrimidinone derivatives and their use for producing pharmaceutical compositions | |
| HUP0101482A3 (en) | Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same | |
| HUP0200517A3 (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 | |
| HUP0002929A3 (en) | 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same | |
| IL127518A (en) | Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect | |
| IL126022A (en) | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders | |
| IL152908A0 (en) | USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS | |
| HUP0004900A3 (en) | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient | |
| HUP0400889A3 (en) | Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound | |
| AU1573100A (en) | Composition of paroxetine methanesulfonate | |
| AU2673201A (en) | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | |
| AU3611099A (en) | Oxindole derivatives used as neurokinin receptor antagonists | |
| HUP0101326A3 (en) | Paroxetine compositions and process for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |